ST-920 (gene therapy for Fabry disease)
GPTKB entity
Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
investigational drug |
| gptkbp:clinicalTrialPhase |
gptkb:STAAR_study
Phase 1/2 |
| gptkbp:developedBy |
gptkb:Sangamo_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
ST-920 (gene therapy for Fabry disease)
|
| gptkbp:indication |
gptkb:Fabry_disease
|
| gptkbp:mechanismOfAction |
AAV2/6 vector delivering GLA gene
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:targetGene |
gptkb:GLA
|
| gptkbp:bfsParent |
gptkb:Sangamo_Therapeutics,_Inc.
|
| gptkbp:bfsLayer |
6
|